Investors initially flocked to Moderna stock due to its successful coronavirus vaccine, leading to billions in revenue and profitability. However, recent declines in vaccine sales and performance of other products have caused setbacks. Vertex Pharmaceuticals emerges as a more promising biotech investment, with leading cystic fibrosis treatments and a diverse product portfolio driving billions in sales and future growth. Vertex’s track record, expanding treatment areas, and strong financials make it a better buy than Moderna.

Read more at Yahoo Finance: Forget Moderna Stock, This is a Much Better Buy